Semaglutide explained: uses, forms, and what the evidence says

Semaglutide is a GLP-1 receptor agonist: a medicine that copies a gut hormone involved in appetite and blood sugar. In the US it is FDA-approved as Wegovy injection and Wegovy tablets (weight reduction and cardiovascular risk reduction; the injection also has a liver indication), Ozempic injection (type 2 diabetes), and a daily tablet for type 2 diabetes sold as Rybelsus and Ozempic tablets. The products differ in dose, route and approved use, so they are not interchangeable.

Sources checked against Europe PMC abstracts and FDA/DailyMed label text: Nov 17, 2026; full text not read for abstract-only claims (recheck on publication date)

Quick answer

Semaglutide is a GLP-1 receptor agonist: a medicine that copies a gut hormone involved in appetite and blood sugar. In the US it is FDA-approved as Wegovy injection and Wegovy tablets (weight reduction and cardiovascular risk reduction; the injection also has a liver indication), Ozempic injection (type 2 diabetes), and a daily tablet for type 2 diabetes sold as Rybelsus and Ozempic tablets. The products differ in dose, route and approved use, so they are not interchangeable.

Which semaglutide product is which

ProductFormApproved uses (adults unless noted)Source
Wegovy injectionOnce-weekly injectionLower the risk of major cardiovascular events in adults with established heart disease and obesity or overweight; reduce excess body weight and keep it off in adults with obesity, or overweight plus a weight-related condition, and in patients 12 and older with obesity; noncirrhotic MASH with moderate to advanced liver fibrosis (accelerated approval)Wegovy label, FDA
Wegovy tabletsOnce-daily tabletCardiovascular risk reduction and weight reduction in adultsWegovy label, FDA
Ozempic injectionOnce-weekly injectionBlood-sugar control in type 2 diabetes; cardiovascular risk reduction in type 2 diabetes with heart disease; reduce kidney disease progression in type 2 diabetes with chronic kidney diseaseOzempic label, FDA
Rybelsus and Ozempic tabletsDaily tablet; not mg-for-mg substitutableBlood-sugar control in type 2 diabetes; cardiovascular risk reduction in type 2 diabetes at high riskRybelsus/Ozempic tablets label, FDA

All uses are alongside diet and physical activity. The Wegovy label says not to combine semaglutide products, or any other GLP-1 receptor agonist.

How it works

Semaglutide activates the GLP-1 receptor. In plain terms, it makes the body respond as if more of a natural fullness-and-insulin signal is present. The Wegovy label says GLP-1 is a natural regulator of appetite and calorie intake, and that GLP-1 receptors are present in brain areas involved in appetite regulation. Animal studies show semaglutide reaches and activates neurons in regions that control food intake. The Ozempic label describes the blood-sugar effect: semaglutide stimulates insulin release and lowers glucagon release, both only when blood sugar is high, with a minor delay in stomach emptying right after meals. The labels say the exact mechanisms of its cardiovascular and kidney benefits have not been established. Stomach side effects such as nausea and diarrhea are common in trials.

What the evidence shows

Weight, in adults without diabetes (STEP 1). In a double-blind randomized trial of 1,961 adults with obesity, or overweight plus a weight-related condition, once-weekly semaglutide 2.4 mg plus lifestyle support was compared with placebo plus lifestyle support for 68 weeks. Mean body weight fell 14.9% with semaglutide and 2.4% with placebo, a difference of 12.4 percentage points (95% CI 11.5 to 13.4). Weight loss of 5% or more occurred in 86.4% vs 31.5%, 10% or more in 69.1% vs 12.0%, and 15% or more in 50.5% vs 4.9%. Nausea and diarrhea were the most common side effects, usually mild to moderate. More people on semaglutide stopped treatment for stomach reasons (4.5% vs 0.8%). Source: Wilding et al., NEJM 2021, doi:10.1056/NEJMoa2032183.

STEP 1 results at week 68

STEP 1 results at week 68

Heart outcomes in adults with obesity and heart disease, without diabetes (SELECT). The trial enrolled 17,604 adults aged 45 or older with BMI of 27 or more and existing cardiovascular disease, and compared semaglutide 2.4 mg weekly with placebo (mean follow-up 39.8 months). Cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 569 of 8,803 people (6.5%) on semaglutide and 701 of 8,801 (8.0%) on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90). Stopping treatment because of adverse events was more common on semaglutide (16.6% vs 8.2%). Source: Lincoff et al., NEJM 2023, doi:10.1056/NEJMoa2307563. The trial was funded by Novo Nordisk, as was STEP 1.

Type 2 diabetes, heart outcomes. In SUSTAIN-6, 3,297 adults with type 2 diabetes (83% with established cardiovascular or kidney disease) received once-weekly semaglutide 0.5 or 1.0 mg or placebo for 104 weeks. The primary composite occurred in 6.6% vs 8.9% (hazard ratio 0.74, 95% CI 0.58 to 0.95). The trial’s prespecified primary hypothesis was non-inferiority. Non-inferiority alone does not establish overall safety. Retinopathy complications were more frequent with semaglutide. In PIONEER 6, 3,183 high-risk adults with type 2 diabetes took oral semaglutide or placebo (median 15.9 months). The composite occurred in 3.8% vs 4.8% (hazard ratio 0.79, 95% CI 0.57 to 1.11), which met its prespecified non-inferiority goal but did not show a statistically significant benefit. Non-inferiority means the medicine was not shown to raise heart risk beyond a set margin. It does not by itself show overall safety or benefit. Sources: Marso et al., NEJM 2016, doi:10.1056/NEJMoa1607141; Husain et al., NEJM 2019, doi:10.1056/NEJMoa1901118.

What this does not establish

  • STEP 1 shows average results in a trial setting with structured lifestyle counseling. Individual results vary, and real-world results can differ.
  • A 68-week trial does not tell us what happens after stopping, or beyond the follow-up period. (Read what is known about weight regain and follow-up after stopping a GLP-1)
  • Results for Wegovy do not transfer to compounded or “research” semaglutide products, which are not FDA-approved and were not tested in these trials.
  • SELECT studied adults with existing heart disease. It does not show the same benefit for people without it.
  • Weight loss and cardiovascular benefit are different outcomes, studied in different populations.

Safety signposts

  • Boxed warning: in rodents, semaglutide caused thyroid C-cell tumors. It is not known whether it does in humans. It is not for people with a personal or family history of medullary thyroid carcinoma or with MEN 2.
  • Labels list severe gastrointestinal reactions and acute kidney injury from volume depletion among the warnings. In people with diabetes, blood sugar should be monitored.
  • Dose, escalation and whether semaglutide fits a person’s health history are decisions for a prescriber. This page does not give dosing advice.

Regulatory context

FDA declared the semaglutide injection shortage resolved on February 21, 2025. FDA says compounded drugs are not reviewed for safety, effectiveness or quality, and should be used only when an approved drug cannot meet a patient’s need.

FAQs

What is semaglutide? A GLP-1 receptor agonist given as a weekly injection or a daily tablet, approved by FDA in the products listed above.

What does human research show about semaglutide? In STEP 1, adults on 2.4 mg lost a mean of 14.9% of body weight at 68 weeks vs 2.4% on placebo. In SELECT, major cardiovascular events occurred in 6.5% vs 8.0% (hazard ratio 0.80) in adults with obesity and heart disease.

What safety or regulatory questions remain? Long-term effects after stopping, individual response, and the status of non-approved versions. Talk with a licensed clinician before starting.

Sources

  1. FDA label, Wegovy (NDA 215256)
  2. FDA label, Ozempic (NDA 209637)
  3. FDA label, Rybelsus and Ozempic tablets (NDA 213051)
  4. Wilding JPH et al. N Engl J Med 2021
  5. Lincoff AM et al. SELECT, N Engl J Med 2023
  6. Marso SP et al. SUSTAIN-6, N Engl J Med 2016
  7. Husain M et al. PIONEER 6, N Engl J Med 2019
  8. FDA, shortage resolution and compounding policy
  9. FDA, concerns with unapproved GLP-1 drugs